SLC6A3 and Parkinson disease: In conclusion, neuroimaging biomarkers in PD have made substantial progress in recent years with the advent of high-field MRI, improved sequences, and dopamine transporter ligands capable of assessing the integrity of the nigrostriatal pathway in vivo.